Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Risk Factors for Chronic Renal Dysfunction in Cardiac Allograft Recipients

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Renal dysfunction is one of the most common and threatening complications in heart transplant recipients. Even if ciclosporin seems to play a central role in inducing renal damage, other factors may concur or predispose to renal injury. In order to identify factors responsible for renal dysfunction, we retrospectively studied a cohort of 114 cardiac transplant recipients during a follow-up period of at least 3 years. The patients had a normal renal function before and 0.5 months after heart transplantation. Doubling of baseline serum creatinine or attainment of serum creatinine steadily above 176.8 µmol/l (2.0 mg/dl) was used as criterion to define the end-point renal dysfunction. A series of clinical and laboratory variables were obtained from the patients’ charts at different time intervals, and their prognostic value for the occurrence of renal dysfunction was calculated by Cox proportional hazards models. 23 out of 114 patients reached the end point after a median time period of 21 months. High serum triglyceride, alanine aminotransferase, alkaline phosphatase, ciclosporin, urea, glucose, and hemoglobin levels were shown to be associated with the development of renal dysfunction. Four variables, i.e., triglyceride, ciclosporin, urea, and alkaline phosphatase, had an independent prognostic value. Our results confirm a role for ciclosporin in inducing renal dysfunction and identify hyperlipidemia and an increased plasma urea level as risk factors for renal dysfunction in heart transplant recipients.

          Related collections

          Most cited references 1

          • Record: found
          • Abstract: found
          • Article: not found

          Explained variation in survival analysis.

           F STARE,  M Schemper (1996)
          Several measures of explained variation have been suggested for the Cox proportional hazards regression model. We have categorized these measures into three classes which correspond to three different definitions of multiple R2 of the general linear model. In an empirical study we compared the performance of these measures and classified them by their adherence to a set of criteria which we think should be met by a measure of explained variation for survival data. We suggest that currently there is no uniformly superior measure, particularly as the concepts of either uncensored or censored populations may lead to different choices. For uncensored populations, a measure by Kent and O'Quigley and the squared rank correlation between survival time and the predictor from a Cox regression model appear recommendable choices. For the latter, censored survival times are terminated using a very recent data augmentation algorithm for multiple imputation under proportional hazards. With censored populations, Schemper's measure, V2, could be considered. We give an introductory example, discuss aspects of application and stress the desirability of routinely evaluating explained variation in studies of survival.
            Bookmark

            Author and article information

            Journal
            NEF
            Nephron
            10.1159/issn.1660-8151
            Nephron
            S. Karger AG
            1660-8151
            2235-3186
            2000
            January 2000
            19 January 2000
            : 84
            : 1
            : 21-28
            Affiliations
            aDepartment of Internal Medicine and Nephrology, bDivision of Cardiology, cDivision of Cardiac Surgery, and dScientific Administration, IRCCS Policlinico San Matteo, University of Pavia, Italy
            Article
            45534 Nephron 2000;84:21–28
            10.1159/000045534
            10644904
            © 2000 S. Karger AG, Basel

            Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

            Page count
            Figures: 3, Tables: 1, References: 41, Pages: 8
            Product
            Self URI (application/pdf): https://www.karger.com/Article/Pdf/45534
            Categories
            Original Paper

            Comments

            Comment on this article